Gen-Probe to Webcast Presentation at the UBS Global Life Sciences Conference
Posted on: Wednesday, 21 September 2005, 18:00 CDT
SAN DIEGO, Sept. 21 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated announced today that the Company will present at the UBS Global Life Sciences Conference in New York on September 26, 2005 at noon Eastern Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investor information section of Gen-Probe's website at http://www.gen-probe.com/. The webcast will be available for 30 days following the event.
About Gen-Probe
Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) used to diagnose human diseases and screen donated human blood. Gen-Probe markets a broad portfolio of products that use the Company's patented technologies to detect infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections. The Company also developed and manufactures the only FDA-approved blood-screening assay for the simultaneous detection of HIV-1 and HCV, which is marketed by Chiron Corporation. In addition, Gen-Probe's TIGRIS instrument is the only fully automated, high-throughput NAT system for diagnostics and blood screening. Gen-Probe has more than 20 years of NAT expertise, and its products are used daily in clinical laboratories and blood collection centers worldwide. Gen-Probe is headquartered in San Diego and employs approximately 900 people. For more information, go to http://www.gen-probe.com/.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-Q for the quarter ended June 30, 2005, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.
Contact: Paula Izidoro Investor Relations 858-410-8904
Gen-Probe Incorporated
CONTACT: Paula Izidoro, Investor Relations of Gen-Probe Incorporated,+1-858-410-8904
Web site: http://www.gen-probe.com/
Source: PRNewswire-FirstCall
Related Articles
- Gen-Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- Gen-Probe to Webcast Four Upcoming Investor Presentations
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- Gen-Probe to Webcast Two Upcoming Investor Presentations
- Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
- 3M Discontinues Collaboration With Gen-Probe to Develop Molecular Tests for Healthcare-Associated Infections
- Gen-Probe to Test Blood for West Nile
- Gen-Probe Receives FDA Approval for PROCLEIX(R) West Nile Virus Blood Screening Assay
 |
 |
User Comments (0)
RSS Feeds